Ideaya Biosciences Stock Price, News & Analysis

IDEAYA Biosciences (NASDAQ:IDYA) has submitted an Investigational New Drug (IND) application to the FDA for IDE892, a potential best-in-class MTA-cooperative PRMT5 inhibitor targeting MTAP-deletion solid tumors. The company plans to initiate a Phase 1 dose escalation trial in MTAP-deleted lung cancer in Q4 2025.

The clinical development strategy includes advancing to combination trials with IDE397, IDEAYA's proprietary MAT2A inhibitor, in H1 2026. The target market is significant, with 15-20% of non-small cell lung cancer (NSCLC) cases being MTAP-deleted. The company will also evaluate IDE892 in other MTAP solid tumor indications, both as monotherapy and in combination with IDE397.

IDEAYA Biosciences (NASDAQ: IDYA) has entered into an exclusive license agreement with Servier for darovasertib, a potential first-in-class treatment for uveal melanoma, a rare and aggressive eye cancer. Under the agreement, IDEAYA will receive $210 million upfront and up to $320 million in milestone payments, plus double-digit royalties on net sales.

The partnership grants Servier regulatory and commercial rights for darovasertib outside the United States, while IDEAYA retains U.S. rights. The drug, which has received FDA Breakthrough Therapy and Fast Track designations, is being evaluated in multiple global clinical trials, including three Phase 3 registrational trials targeting neoadjuvant, adjuvant, and metastatic settings.

IDEAYA Biosciences (NASDAQ:IDYA) announced the acceptance of an abstract for oral presentation at the 2025 Society for Melanoma Research Congress in Amsterdam. The presentation will feature the first-ever median overall survival data from their Phase 1/2 trial evaluating the combination of darovasertib and crizotinib in first-line metastatic uveal melanoma (mUM).

The study, known as OptimUM-01, includes data from over 40 patients. Dr. Meredith McKean from Sarah Cannon Research Institute will present the findings at the congress, which takes place from October 25-28, 2025. The detailed data from the abstract will be disclosed at a future date.

IDEAYA Biosciences (NASDAQ: IDYA) announced the granting of inducement stock options to four newly hired employees on August 28, 2025. The Compensation Committee approved non-qualified stock options to purchase 139,800 shares of common stock under the company's 2023 Employment Inducement Incentive Award Plan.

The stock options have an exercise price of $24.93 per share, matching IDEAYA's closing price on the grant date. The options feature a 10-year term with a four-year vesting schedule: 25% vesting after one year and the remaining 75% vesting monthly over three years, contingent on continued employment.

IDEAYA Biosciences (NASDAQ: IDYA), a precision medicine oncology company, has announced its participation in three major investor events in September 2025. The company will participate in a fireside chat at the Cantor Global Healthcare Conference on September 3rd, host its 10-Year Anniversary R&D Day on September 8th featuring clinical data updates and KOL Dr. Arun D. Singh, and attend the Morgan Stanley Global Healthcare Conference on September 9th for one-on-one meetings.

The R&D Day will showcase multiple clinical data updates, outline future catalysts, and review long-term portfolio strategy. Live audio webcasts will be available on the company's investor relations website, with replays accessible for 30 days post-event.

IDEAYA Biosciences (NASDAQ:IDYA) will host its 10-Year Anniversary R&D Day on September 8, 2025 in New York from 8:00-10:30am EST. The event will showcase the company's progress and future growth strategy, featuring presentations on multiple clinical programs.

Key highlights include new clinical data presentations on darovasertib in neoadjuvant uveal melanoma, IDE849 (DLL3 TOP1 ADC), and IDE397 (MAT2A). Dr. Arun D. Singh from Cleveland Clinic will present Phase 2 trial data of darovasertib and discuss the Phase 3 OptimUM-10 trial design. The agenda also covers IDE892 (PRMT5) development and the company's AI/ML discovery capabilities.

IDEAYA Biosciences (Nasdaq: IDYA) reported Q2 2025 financial results and significant pipeline progress. The company maintains a strong financial position with $992 million in cash, expected to fund operations into 2029. Key developments include the Phase 2/3 trial of darovasertib/crizotinib combination in metastatic uveal melanoma, with over 350 patients enrolled and median PFS data expected by year-end 2025.

The company plans three IND submissions by year-end 2025 and will present multiple clinical data updates across its pipeline. Notable upcoming milestones include Phase 2 data from over 90 primary uveal melanoma patients at ESMO and Phase 1 data from over 70 SCLC patients treated with IDE849 at WCLC. Financial results show R&D expenses of $74.2 million and a net loss of $77.5 million for Q2 2025.

[ "Strong cash position of $992 million expected to fund operations into 2029", "Phase 2/3 trial of darovasertib/crizotinib successfully enrolled over 350 patients", "Multiple near-term catalysts with six clinical data updates expected by year-end", "Three new IND submissions planned by year-end 2025", "Expansion of commercial and medical affairs team in preparation for potential product launch" ]

IDEAYA Biosciences (NASDAQ: IDYA) announced the granting of inducement stock options to a new employee. The Compensation Committee approved non-qualified stock options to purchase 31,400 shares of common stock under the company's 2023 Employment Inducement Incentive Award Plan.

The stock options were granted at an exercise price of $24.35 per share, matching IDEAYA's closing price on the grant date. The options have a 10-year term and will vest over four years, with 25% vesting after the first year and the remaining 75% vesting monthly over the following three years, subject to continued employment.

IDEAYA Biosciences (NASDAQ:IDYA) announced that results from their Phase 2 study of neoadjuvant darovasertib in primary uveal melanoma will be presented at ESMO 2025 in Berlin. The study includes data from over 90 patients across plaque brachytherapy and enucleation-eligible cohorts.

The presentation will highlight darovasertib's potential impact on disease management, particularly notable as it has received FDA Breakthrough Therapy Designation for neoadjuvant use in uveal melanoma patients requiring enucleation. The company has also initiated OptimUM-10, a global Phase 3 neoadjuvant registrational trial, in Q3 2025.